Kamada Ltd - KMDA Net earnings per one share for the last twelve months

Kamada Ltd (KMDA) - corporate logo

As a biopharmaceutical business, Kamada Ltd. (KMDA) strictly adheres to ESG principles by implementing water purification systems and safe waste processing. Financial stability relies on a synthesis of plasma protein production and the resale of foreign brands. This daily price action reflects a monetary market trend for EPS TTM of 21.60, while profit growth remains constrained by the cost of donor raw materials despite stable sales of therapeutic products.

KMDA: kamada.com Net earnings per share for the last 12 months 02/11/2024 - 11/16/2026

Kamada Ltd. - analytical breakdowns and key metrics (KMDA)

- stock quotes and analyst forecast:
Fundamental company valuation:KMDA - Kamada Ltd
Brand item of Kamada Pharma

This indicator captures the net profit per share dynamics over the last twelve months relative to the previous year. By analyzing the EPS YoY TTM growth efficiency metric, an investor assesses the real scaling speed of the business capitalization. The monopoly status of Kamada Ltd. (KMDA) in the plasma-replacement drug segment allows the company to transform the high cost of injections into stable profit growth. The steady trajectory of the curve confirms the issuer's solvency and justifies the premium valuation of the assets.

Competitor analysis

Earnings per one share for the last 12 months VRTX|ALNY: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Insmed Inc (INSM)|UTHR (United Therapeutics Corporation) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BMRN (BioMarin)|Net earnings per share for the last 12 months BBIO (BridgeBio)|BGM: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Cogent Biosciences, Inc. COGT|XERS (Xeris Biopharma Inc) - Earnings per one share for the last 12 months|Keros Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ARCT (Arcturus Therapeutics)|ETON: Net earnings per share (EPS TTM)|Fulcrum Therapeutics Inc (FULC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Rein Therapeutics Inc. RNTX|gelteq.com - Net earnings per share (EPS TTM)|AYTU - Net earnings per share (EPS TTM)|CMMB: Net earnings per share (EPS TTM)|SRx Health Solutions Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Polyrizon Ltd|AEZS (Aeterna Zentaris) - Earnings per share for the last four quarters|Earnings per share for the last twelve months CTD Holdings (CYTH)|INZY: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Reneo Pharmaceuticals Inc. RPHM|Net earnings per share for the last four quarters COSCIENS Biopharma Inc. (CSCI)